Liposome Technology Inc.'s patience in licensing Amphocil, its liposomal form of the antifungal agent amphotericin B, has paid off.

In the tepid funding environment, many biotech companies are eager to find a development partner at an early stage of the game. In return, the biotech company receives a royalty on gross profits, usually around 10 to 15 percent.